Articles On Rhythm Biosciences (ASX:RHY)

Rhythm Biosciences reports it has attained all key milestones for 2024 Company receives delivery of second generation ColoSTAT beta release candidate multiplex kits Rhythm has a market-entry roadmap for second generation ColoSTAT Assay wit...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Rhythm Biosciences’ new CEO Dr David Atkins is on a mission to improve early diagnosis of bowel cancer Company raises $3.5 million in a placement supported by  several  new  institutional,  professional  and  sophisticated investors Secon...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

Telix Pharmaceuticals’ brain cancer diagnostic could leapfrog over its kidney cancer assay to be its second commercialised product Rhythm Biosciences still hopes to flush the bowel cancer ‘poo test’ into history Today’s quarterly reports s...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 pati...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX struggled to rise, with gains tempered by CSL and Seek CSL’s earnings and cautious forecast hurt the health sector Trump discussed policies with Musk amid a busy day for the markets   After a flat start, Aussie stocks started edging h...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improve...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

While most developers of health diagnosis tools scurry off to the capacious US market, Bcal is happy to use Australia as the springboard for what will be the country’s first blood-based breast cancer assay. “It’s a passion of ours to launch...

“We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT,” said...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 rises by a broken fingernail and just looks flat IT gains offset by Energy losses as uranium stocks get hit hard Really peculiar bunch of small cap winners led by AVA Risk and Venture Minerals   Local markets have wavered either...

Together with the Baker Institute, Rhythm identifies best five-biomarker combination that can target the various stages of lung cancer The company used a cohort of 70 healthy and cancerous patients It will now move towards a larger s...

Rhythm Bio says biomarker findings warrant the case for new investment in R&D Dental focused SDI says product registration globally is becoming more difficult to achieve   Rhythm Bio says new R&D investment is warranted after this...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

Benchmark ASX index closes -0.6% lower, but gains for the week ASX Sectors led by Utilities which jumped +5.0% since Monday Small caps led by HOR, FTZ, SWF   The ASX200 has closed lower on Friday, ending the session -0.6% lower, but ahe...

Benchmark ASX index finishes ever so slightly up ASX Sectors led by Financial, IT, Property and Materials Small cap gainers: RBL, PIL, and LPI   Here’s how we ended on Thursday. Local markets largely did okay, and then wilted when we go...

Stockhead’s Top 10 at shortly-before-11-ish, produced approximately on time, and largely dependent on whether this god-awful NBN decides it’s “too hot outside” to function properly. Top 10 highlights the best (and sometimes worst) performin...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The market may be falling for a fourth day in a row, but that hasn't stopped a couple of ASX healthcare shares from charging higher today. Here's what is getting investors excited about them on Wednesday: Race Oncology Ltd (ASX: RAC) The...

Rhythm Biosciences (ASX:RHY) has provided an update on its cancer diagnostics technology platform expansion program in breast cancer.

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Cancer diagnostics technology company Rhythm Biosciences (ASX:RHY) says it has further progressed its market entry strategy for ColoSTAT in the UK by establishing a fully-owned subsidiary.

Lumos soars after US FDA approval for FebriDx rapid, point-of-care test Emyria will buy the Pax Centre for $1.7 million following psychedelic medicine law changes in Australia Rhythm Biosciences establishes UK subsidiary as part of strateg...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Advance ZinkTek chairman buys up $1.78 million worth of shares increasing his holding to more than 51% Youth apparel retailer Universal Holdings sees several of its directors bullish despite economic headwinds Kelsian Group non-executive d...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Rhythm BioSciences (ASX:RHY) progresses its market entry of ColoSTAT into the United Kingdom, following UKCA mark certification The company penned a new partnership with London-based LINK Medical Solutions to assist with a phased approach...